Antimicrobial Stewardship & Healthcare Epidemiology (Jan 2022)
Antibodies in healthcare personnel following severe acute respiratory syndrome coronavirus virus 2 (SARS-CoV-2) infection
- Rachel E. Bosserman,
- Christopher W. Farnsworth,
- Caroline A. O’Neil,
- Candice Cass,
- Daniel Park,
- Claire Ballman,
- Meghan A. Wallace,
- Emily Struttmann,
- Henry Stewart,
- Olivia Arter,
- Kate Peacock,
- Victoria J. Fraser,
- Philip J. Budge,
- Margaret A. Olsen,
- Carey-Ann D. Burnham,
- Hilary M. Babcock,
- Jennie H. Kwon,
- for the CDC Prevention Epicenters
Affiliations
- Rachel E. Bosserman
- ORCiD
- Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
- Christopher W. Farnsworth
- Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri
- Caroline A. O’Neil
- ORCiD
- Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
- Candice Cass
- Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
- Daniel Park
- Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
- Claire Ballman
- Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri
- Meghan A. Wallace
- Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri
- Emily Struttmann
- ORCiD
- Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
- Henry Stewart
- ORCiD
- Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
- Olivia Arter
- Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
- Kate Peacock
- Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
- Victoria J. Fraser
- ORCiD
- Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
- Philip J. Budge
- ORCiD
- Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
- Margaret A. Olsen
- ORCiD
- Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
- Carey-Ann D. Burnham
- Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri
- Hilary M. Babcock
- ORCiD
- Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
- Jennie H. Kwon
- Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
- for the CDC Prevention Epicenters
- DOI
- https://doi.org/10.1017/ash.2022.231
- Journal volume & issue
-
Vol. 2
Abstract
In a prospective cohort of healthcare personnel (HCP), we measured severe acute respiratory syndrome coronavirus virus 2 (SARS-CoV-2) nucleocapsid IgG antibodies after SARS-CoV-2 infection. Among 79 HCP, 68 (86%) were seropositive 14–28 days after their positive PCR test, and 54 (77%) of 70 were seropositive at the 70–180-day follow-up. Many seropositive HCP (95%) experienced an antibody decline by the second visit.
